Related Experiment Video

Updated: Jul 24, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.5K

Exploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activity

Asiye Gok Yurttas1, Mustafa Fatih Dasci2

  • 1Department of Biochemistry, Faculty of Pharmacy, Istanbul Health and Technology University, Istanbul, Turkey.

Pathology, Research and Practice
|July 8, 2023
PubMed
Abstract

Insights

Linagliptin (LG) effectively inhibits osteosarcoma cell growth and induces cell death. This study explored LG

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Repurposing existing drugs offers a rapid strategy for novel anticancer agent discovery.
  • Osteosarcoma (OS) is a primary bone cancer with treatments causing significant morbidity.
  • Investigating linagliptin (LG) for anti-OS activity in Saos-2 cells is crucial.

Purpose of the Study:

  • To systematically evaluate the anticancer effects of linagliptin (LG) on osteosarcoma.
  • To determine the impact of LG on Saos-2 cell viability and apoptosis.
  • To elucidate the molecular mechanisms underlying LG's action in osteosarcoma.

Main Methods:

  • Cell viability assessed using MTT assays.
  • Apoptosis evaluated through flow cytometry.
  • Gene expression profiling via qPCR arrays to analyze cancer pathways.

Main Results:

  • Linagliptin significantly reduced Saos-2 and hFOB1.19 cell viability (p < 0.001).
  • LG treatment markedly increased apoptosis in Saos-2 (p < 0.001) and hFOB1.19 (p < 0.05) cells.
  • qPCR analysis revealed LG's impact on cancer-related gene expression.

Conclusions:

  • Linagliptin demonstrates potent inhibition of osteosarcoma cell proliferation.
  • LG effectively induces programmed cell death (apoptosis) in osteosarcoma cells.
  • LG exerts its effects by downregulating key genes within cancer pathways.
Keywords:
Anti-cancerHFOB1.19LinagliptinOsteosarcomaQPCRSaos-2

More Related Videos

Improved Visualization of Lung Metastases at Single Cell Resolution in Mice by Combined In-situ Perfusion of Lung Tissue and X-Gal Staining of lacZ-Tagged Tumor Cells08:47

Improved Visualization of Lung Metastases at Single Cell Resolution in Mice by Combined In-situ Perfusion of Lung Tissue and X-Gal Staining of lacZ-Tagged Tumor Cells

Published on: August 21, 2012

17.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214